Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04021862 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis and Eczema, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 17
- Study locations
NCT04021862: Completed Phase 2 study of Atopic Dermatitis and Eczema, sponsored by Janssen Research & Development.
NCT04021862 is a Phase 2 study of Atopic Dermatitis and Eczema that has completed, run by Janssen Research & Development. The registered enrollment target is 87 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (86% lower). The trial reports 17 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04021862, a Phase 2 study of Atopic Dermatitis and Eczema, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 17
- Study locations
Study Summary
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
Primary Outcome
Percentage of participants achieving EASI-75 at Week 16 were reported. EASI-75 response was defined as at least 75% improvement from baseline in EASI total score. The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-poin
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bermekimab Monoclonal Antibody
Study Locations (17)
Florida
- Florida Academic Dermatology Centers - Coral Gables
- Doral Medical Research - Doral
- Floridian Research Institute - Miami
- Florida International Medical Research - Miami
- Premier Research Associate, Inc - Miami
- CNS HealthCare - Orlando
- Avita Clinical Research - Tampa
- Forcare Clinical Research Inc - Tampa
Indiana
- Dawes Fretzin Clinical Research Group - Indianapolis
- Randall Dermatology & Cosmetic Surgery - West Lafayette
California
- Beach Clinical Research Inc - Huntington Beach
Georgia
- Advanced Medical Research - Sandy Springs
Michigan
- Revival Research Institute LLC - Troy
Ohio
- ClinOhio Research Services - Columbus
Tennessee
- Helios Clinical Research, LLC - Milan
Texas
- Progressive Clinical Research - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2019-10-16 |
| Est. Completion | 2020-11-19 |
| Phase | Phase 2 |
What the finished NCT04021862 record still lists
NCT04021862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04021862 lists 17 locations in 9 states (Florida, Indiana, California).
Frequently Asked Questions
What is clinical trial NCT04021862 about?
NCT04021862 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis". A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
What is the current status of trial NCT04021862?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2019-10-16. Estimated completion is 2020-11-19.
What conditions does trial NCT04021862 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema.
What interventions are being tested in trial NCT04021862?
The interventions under investigation include: Placebo (DRUG), Bermekimab Monoclonal Antibody (DRUG).
Who is sponsoring clinical trial NCT04021862?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04021862 being conducted?
This trial has 17 study locations across California, Florida, Georgia, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04021862's enrollment target sits among peer trials
87 94th of 150 higher than 57 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI